key: cord-0947113-phkqdkav
authors: Strauss, Alexandra T.; Chang, Amy; Alejo, Jennifer L.; Chiang, Teresa P.‐Y.; Hernandez, Nicole F.; Zeiser, Laura B.; Boyarsky, Brian J.; Avery, Robin K.; Tobian, Aaron A. R.; Levan, Macey L.; Warren, Daniel S.; Massie, Allan B.; Garonzik‐Wang, Jacqueline M.; Segev, Dorry L.; Werbel, William A.
title: Severe acute respiratory syndrome coronavirus 2 antibody response to a third dose of homologous messenger RNA vaccination in liver transplantation recipients
date: 2022-05-09
journal: Liver Transpl
DOI: 10.1002/lt.26472
sha: dbe167a626a612e22128e7908a11df63848730e1
doc_id: 947113
cord_uid: phkqdkav

nan

To the editor, Liver transplantation (LT) recipients have attenuated antibody response to the two-dose messenger RNA (mRNA) vaccine series against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). [1] [2] [3] Additional vaccine doses, best studied in the kidney transplantation population, may improve response, yet many solid organ transplantation recipients appear to continue to have a poor response despite additional doses. [4, 5] We aimed to measure antibody levels before and after a third mRNA vaccine dose (D3) in a large cohort of LT recipients to understand vaccine immunogenicity and the demographic, transplantation, and vaccine type associated with sero-response.

LT recipients in our longitudinal observational cohort who received three doses of homologous mRNA vaccines and had antibody levels measured both after dose 2 (D2) and after D3 were identified. Participants with multiorgan transplantation (n = 37), pre-dose 1 (D1) SARS-CoV-2 infection (n = 11), or SARS-CoV-2 breakthrough infection (n = 3 before D3; n = 17 after D3) as antibody interpretation would not be reflective of the overall LT cohort. The pre-D3 level was defined as the last anti-spike antibody level collected between D2 and D3; the level was repeated 1 month after D3. Samples were tested with clinical anti-spike assays: Roche Elecsys Anti-SARS-CoV-2 enzyme immunoassay (EIA) (anti-receptor-binding domain [RBD], positive ≥0.8 U/ml; ceiling 2500 U/ml) or EUROIMMUN EIA (anti-S1, positive ≥1.1 AU).

There were 148 included participants who completed three homologous doses of BNT162b2 (49%) or mRNA-1273 (51%) vaccines between June 5, 2021, and December 21, 2021 ( Risk factors significantly associated with seronegativity after D3 were antimetabolite use (90% vs. 41%; p = 0.005), and proximity to transplantation (3 vs. 6 years; p = 0.014). No patient made substantial decreases to their anti-metabolite dosage before and after D3. Receipt of the BNT162b2 series (80% vs. 47%; p = 0.054) was also more common in seronegative participants, but this was not statistically significant. The median anti-RBD level increased from before to after D3 by at least 13.6-fold (from 184 U/ml to >2500 U/ml), and median anti-S1 level increased by 3.6-fold (from 2.50 AU to 8.94 AU) after D3 ( Figure 1 ).

As post hoc analysis, we evaluated the excluded group of participants that had breakthrough infections after D1. Among 20 participants who reported T A B L E 1 Baseline characteristics of LT recipients who completed three doses of homologous SARS-CoV-2 vaccines and categorized by positive versus negative levels at 1 month after D3

Antibody level after D3 F I G U R E 1 Violin plot of pre-D3 versus 1 month post-D3 antibody level, categorized by assay. Reference line delineates positive cut-offs for anti-RBD (≥0.8 U/ml) and anti-S1 (≥1.1 AU). Anti-RBD assay is measured along a log 10 scale on the y-axis. (A) Roche EIA; (B) EUROIMMUN EIA breakthrough infection after D1, 17 occurred at a median (IQR) of 125 (116-150) days after D3. Among those 17 participants, 4 (24%) were seronegative after D3. Of the 13 seropositive patients, the median (IQR) post-D3 anti-RBD level was 2500 (1932-2500) U/ml. The median anti-S1 level after D3 was 8.94 AU.

Most LT recipients demonstrated excellent antibody response to mRNA vaccination, with improved seroconversion and titer levels after D3. This response is greater than that reported for other organ recipients, yet, particularly amid the changing variant landscape, this report does not provide direct evidence of seroprotection. Notably, a subgroup of recipients on antimetabolites and/or closer to transplantation remains seronegative after D3, and thus may warrant additional monitoring and protective interventions given the likely ongoing high risk for SARS-CoV-2 infection. Future directions include durability of vaccine response, including assessing for reversions after additional doses, with a link to clinical outcomes.

Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months

Antibody response to severe acute respiratory syndrome-coronavirus-2 messenger RNA vaccines in liver transplant recipients

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series

Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients

The authors thank the participants of the Johns Hopkins COVID-19 Transplant Vaccine Study, without whom this work would be possible. They also thank study team members, including Mayan Teles, BS; Jake D.